BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cytonet GmbH & Co. KG Announce International Collaboration In Cell Therapy


1/16/2007 10:06:54 AM

WEINHEIM, Germany and DURHAM, North Carolina, January 16 /PRNewswire/ -- Cytonet GmbH & Co. KG, Weinheim, and Vesta Therapeutics Inc., Durham (North Carolina, USA), have signed a mutual strategic collaboration agreement. In the context of this collaboration, a GMP facility in accordance with European standards will be constructed on the premises of Vesta Therapeutics, where liver cell products for Cytonet's clinical trials will be produced in the coming years. The first international multi-center studies worldwide should verify the efficacy and clinical suitability of Cytonet's liver cell therapy, helping to promote its authorization in the EU.

Cytonet has managed in recent years to refine techniques of cell isolation and processing to the extent that human liver cells can be obtained in medicinal product quality in a routine production process. This means that the curative treatment of various liver diseases is possible in the sense of genuine "regenerative medicine". Accordingly, vital liver cells from donor organs that cannot be used for transplantation take over essential metabolism and detoxification tasks in the diseased liver. Through the implementation of GMP (Good Manufacturing Practice) for cell isolation, the stringent requirements of German and European drug manufacturing are fulfilled. In addition, the Commercial Regulatory Authority of Lower Saxony, in agreement with the Paul-Ehrlich Institute, have granted Cytonet a manufacturing authorization on this basis, the first time ever for a liver cell product.

With the new types of German production technology, Vesta Therapeutics supplements its own facility know-how.

Vesta Therapeutics Inc., a private company manufacturing cell therapy products, is convinced that this will be a successful collaboration. Mark Johnston, President since 2004, emphasizes the advantages for both sides of this promising partnership: "With Cytonet's technologies, Vesta Therapeutics will become the only producer of European GMP compliant cell-therapeutic liver preparations in the United States. This is an important step on the way to establishing a worldwide, standardized liver cell therapy". "This will be a very productive collaboration, and we are delighted to have entered into this relationship." Additionally, Vesta Therapeutics has an allowed IND from the US FDA for a liver cell therapy and plans to begin trials in the US in the coming year.

"Vesta Therapeutics is a rapidly growing company in the field of cell therapy, with an impressive product and patent portfolio. They are the ideal American partner. With the production of clinical study medication according to European standards, which is now possible there, we are taking a big step together towards the forthcoming approval of liver cell therapy", declares Dr. Dr. Wolfgang Rudinger, one of the two Cytonet directors along with Michael J. Deissner, confirming the excellent prospects for collaboration. The Weinheim biotechnology company was founded in 2000 and today considers itself the market leader in cell therapy in Germany. Cytonet operates cell production and development facilities in Hanover and Heidelberg.

Press contact: Michael Tschugg Cytonet GmbH & Co. KG Albert-Ludwig-Grimm-Str. 20 D-69469 Weinheim Phone: +49-(0)-62-01-25-98-19 Fax: +49-(0)-62-01-25-98-28 E-Mail: presse@cytonet.de

Cytonet GmbH & Co. KG

CONTACT: Press contact: Michael Tschugg, Cytonet GmbH & Co. KG,Albert-Ludwig-Grimm-Str. 20, D-69469 Weinheim, Phone:+49-(0)-62-01-25-98-19, Fax: +49-(0)-62-01-25-98-28,E-Mail:presse@cytonet.de



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES